Sage: Phase 3 Study Of Zuranolone On Major Depressive Disorder Meets Primary & Secondary Endpoints

WESTON (dpa-AFX) - Sage Therapeutics Inc. (SAGE) and Biogen Inc. (BIIB) said that the phase 3 CORAL study in people with major depressive disorder met its primary and key secondary endpoints. The

Related Keywords

Kostenloser Wertpapierhandel ,Sage Therapeutics Inc ,Biogen Inc ,Care Antidepressant ,Care Co Initiated ,New Drug Application ,Sage ,Hase ,Study ,Zuranolone ,Major ,Depressive ,Disorder ,Meets ,Primary ,Secondary ,Endpoints ,